Tryptamine Therapeutics (AU:TYP) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tryptamine Therapeutics has announced successful completion of its Phase 1b trial for TRP-8803, an innovative IV-infused psilocin formulation. The study confirmed the safety and efficacy of TRP-8803 in achieving controlled psychedelic states with faster onset compared to oral psilocybin. This development paves the way for Phase 2 trials, potentially offering new therapeutic options for neuroplastic treatment.
For further insights into AU:TYP stock, check out TipRanks’ Stock Analysis page.